System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Adriaan G Holleboom is an expert in Hepatology at Amsterdam University Medical Center (Netherlands). As of October 2026, ScienceLeadR ranks Adriaan G Holleboom in the top 1% of experts worldwide for MASH, and in the top 1% of experts in the Netherlands for Alcohol-Induced Disorders and Fatty Liver, Alcoholic. Adriaan G Holleboom has authored 133 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 3 of them ongoing. SLR score: 632 (community average: 125). How the SLR is computed.

LeadR Profile

Adriaan G Holleboom Amsterdam University Medical Center Netherlands
632 ScienceLeadR Reputation 632

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology - Biochemistry - Endocrinology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2008 - 2026
Source: PubMed

Amsterdam University Medical Center

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 133

Citations

Citations: 5 171 1st author: 12 Last author: 34 Unique author: 0

Main journals

JHEP Rep 9
Atherosclerosis 8
Hepatology 6
J Lipid Res 6
Circulation 5

Best Journals

Lancet Gastroenterol Hepatol 3
N Engl J Med 2
Nat Med 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Unexplained recurrent diffuse bleeding diathesis as a manifestation of nonaneurysmal intimomedial mucoid degeneration.
PMID 42920794 — shock, hemorrhagic, hemorrhage, absenteeism, hematoma, aneurysm, arteries, disease susceptibility		Res Pract Thromb Haemost20260
Hepatic Steatosis and Cardiovascular Risk in Obesity: A 10-Year Follow-Up Study From Childhood Into Young Adulthood.
PMID 42683934 — pediatric obesity, follow-up studies, obesity		Pediatr Obes20260
Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management.
PMID 42617506 — liver diseases, multiple chronic conditions, liver		JHEP Rep20264
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study.
PMID 42498741 — serum, fibrosis, elasticity imaging techniques, non-alcoholic fatty liver disease, liver, biomarkers		Nat Med Top journal20268
Exploring the liver-kidney axis in the Ghanaian population: the RODAM prospective study.
PMID 42495747 — incidence, global health, albuminuria, transferases, kidney, transaminases, liver, biomarkers, prospective studies		J Glob Health20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 3
N/A 2
Phase 2 2

By status:

Recruiting 4
Completed 3

By type:

Interventional 5
Observational 2

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 6

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes)
2025-522674-36-00 — liver diseases, liver		Phase 3Recruiting2026
Synbiotics and Fecal Microbiota Transplantation to Treat Non Alcoholic Steatohepatitis
NCT05821010 — liver diseases, oligosaccharides, administration, oral, fecal microbiota transplantation, non-alcoholic fatty liver disease, liver, synbiotics, alcoholics, prebiotics, capsules, probiotics, therapeutics, fatty liver, gastrointestinal microbiome, transplantation, fatty liver, alcoholic, microbiota		Phase 2Recruiting2023
Global Research Initiative for Patients Screening on MASH
NCT05651724 — diabetes mellitus, hypertension, liver cirrhosis, fibrosis, non-alcoholic fatty liver disease, liver, patient care, obesity, research, fatty liver, metabolic syndrome, diabetes mellitus, type 2		N/ARecruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS